Inflammation, Immune Activation and Portal Hypertension in Alcoholic Hepatitis (Heliac)

This study has been completed.
Information provided by (Responsible Party):
Thomas Damgaard Sandahl, University of Aarhus Identifier:
First received: October 8, 2009
Last updated: September 14, 2011
Last verified: September 2011
The purpose of this study is to investigate the role of endotoxins and the endotoxin mediated immune activation pathway in patients with alcoholic hepatitis. Also, to determine the effect of Liver assist (liver dialyses) intervention on these parameters in patients with severe alcoholic hepatitis.

Condition Intervention
Alcoholic Hepatitis
Device: Prometheus Liver Dialysis system (Fresenius Medical Care)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Inflammation, Immune Activation and Portal Hypertension in Alcoholic Hepatitis. A Pato-etiological Study With Focus on the Endotoxin Pathway.

Resource links provided by NLM:

Further study details as provided by University of Aarhus:

Primary Outcome Measures:
  • Serum endotoxin levels [ Time Frame: one year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Endotoxin activation pathway proteins [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: August 2009
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: albumin liver dialysis Device: Prometheus Liver Dialysis system (Fresenius Medical Care)
6 hour dialysis for 3 consecutive days
Other Name: The prometheus albumin dialysis by Fresenius Medical Care
No Intervention: Standard medial care without dialysis


Ages Eligible for Study:   18 Years to 69 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Patients with alcoholic hepatitis based on the following criteria

  • Alcohol intake for 6 consecutive months above 40g /day, at admission or 3 months earlier.
  • Serum bilirubin level above 80 mmol/l
  • exclusion of other types of liver disease.
  • Liver biopsy when diagnosis is unclear.

Exclusion Criteria:

  • Heart failure
  • Pregnancy
  • non fluent danish speakers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00992888

Department of Medicine V, Aarhus University Hospital
Aarhus, Denmark, 8000
Sponsors and Collaborators
University of Aarhus
Study Director: Hendrik Vilstrup, Prof Department of Medicine V, Aarhus University Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Thomas Damgaard Sandahl, Dr, University of Aarhus Identifier: NCT00992888     History of Changes
Other Study ID Numbers: Heliac-01 
Study First Received: October 8, 2009
Last Updated: September 14, 2011
Health Authority: Denmark: Danish Dataprotection Agency

Keywords provided by University of Aarhus:
Alcoholic Hepatitis
Liver dialysis
Innate immunity
Toll Like receptors

Additional relevant MeSH terms:
Hepatitis, Alcoholic
Hepatitis A
Hypertension, Portal
Alcohol-Induced Disorders
Alcohol-Related Disorders
Chemically-Induced Disorders
Digestive System Diseases
Enterovirus Infections
Hepatitis, Viral, Human
Liver Diseases
Liver Diseases, Alcoholic
Picornaviridae Infections
RNA Virus Infections
Substance-Related Disorders
Virus Diseases processed this record on May 24, 2016